U.S. Markets closed

Patrys Limited (PAB.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0050.00 (0.00%)
At close: 12:13PM AEST

Patrys Limited

Equitable House
Suite 614
Melbourne, VIC 3000
61 3 9670 3273

Full Time Employees

Key Executives

Dr. James A. Campbell Ph.D., MBAChief Exec. Officer, Managing Director and Director220kN/AN/A
Ms. Melanie Jaye Leydin B.Bus (Acc/Law), CACompany Sec.60kN/A44
Dr. Deanne Greenwood Ph.D., MBAVP of Bus. Devel. & Intellectual PropertyN/AN/AN/A
Ms. Valentina Dubljevic MBB, BScVP of Scientific & Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Patrys Limited, together with its subsidiaries, develops natural human antibody-based therapeutic products for the treatment of cancer in Australia. The company’s clinical products include PAT-SM6, a natural human antibody used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers that include multiple myeloma; and PAT-SC1, an antibody for treating gastric cancer. Its late stage preclinical products comprise PAT-LM1, a natural human antibody, which is used in the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10 a novel autoantibody that penetrates cancer cell nuclei, damage DNA, inhibit DNA repair, and kill DNA repair-deficient cancer cells. The company was founded in 2006 and is based in Melbourne, Australia.

Corporate Governance

Patrys Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.